Roche Launches Elecsys Epstein-Barr Virus (EBV) Immunoassay Panel to Identify EBV Infection Staging

 Roche Launches Elecsys Epstein-Barr Virus (EBV) Immunoassay Panel to Identify EBV Infection Staging

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Shots:

  • Roche launches Elecsys EBV immunoassay panel in countries accepting the CE mark. The Elecsys EBV panel consists of three immunoassays: Elecsys EBV IgM, Elecsys EBV VCA IgG, and Elecsys EBV EBNA IgG to detect Abs specific for the infection stage
  • The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, resulting in potentially faster diagnosis for patients
  • The EBV panel can be used in other acute infections, such as missed HIV infections. Additionally, Roche will submit the regulatory filing to the US FDA for the EBV panel in future

Click here to­ read full press release/ article | Ref: Roche | Image: Krauthammer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post